Lactobacillus acidophilus YT1,
does it really help with Improved menopausal symptoms, including hot flashes, and quality of life?
research showsMENOLACTO is rated C because a 12-week multicenter randomized double-blind placebo-controlled trial found favorable signals for total KMI and the physical, psychosocial, vasomotor, and sexual MENQOL domains. Only 67 participants were analyzed, KMI and MENQOL are participant-reported symptom scales, and objectively counted hot-flash frequency or a physiologic vasomotor measure was not the central endpoint. This single branded strain and product lacks independent replication and long-term clinical testing, and company researchers were coauthors, so rule ②-b caps the grade at C. Korean individual recognition documents that a product assessment exists but was not used to raise the evidence grade.
ads claimMarketing turns one 12-week subjective-scale trial into claims such as menopause probiotic, hot-flash solution, and hormone-free replacement. The YT1 result also cannot be transferred to other L. acidophilus strains or generic probiotics.
Useful facts when choosing a product
- MENOLACTO uses the specific L. acidophilus YT1 strain deposited as KCCM11808P. Probiotic effects depend on species, strain, and dose, so another acidophilus product cannot substitute for the studied product.
- The clinical-trial dose was 1×10^8 CFU per day for 12 weeks. Storage conditions and the viable count guaranteed at the end of shelf life should be checked on the actual label.
- The trial found no clear between-group safety problem in adverse events, laboratory tests, vital signs, FSH, estradiol, or endometrial thickness. Its size and duration cannot establish long-term or rare harms.
- Probiotic adverse effects are usually mild in healthy people, but severe illness, immunocompromise, or a central venous catheter can increase the rare risk of infection and warrants medical advice.
What the research actually shows
Lim and colleagues assigned women aged 40 to 60 years with menopausal symptoms to MENOLACTO at 1×10^8 CFU/day or placebo for 12 weeks. Among 67 analyzed participants, total KMI, several modified-KMI items, and all four MENQOL domains improved relative to placebo, while FSH, estradiol, and endometrial thickness did not differ materially between groups. The two-center study nevertheless tested one branded product and included Huons employees as authors. No independent trial was identified that reproduced objective hot-flash frequency, sleep, or long-term quality-of-life outcomes with the same YT1 strain.
Why this is classified as C (53)
The positive KMI and MENQOL findings from a 12-week multicenter double-blind trial are genuine human evidence. The sample of 67, subjective composite outcomes, a single branded strain and product, company coauthors, and no independent long-term replication invoke the rule ① and rule ②-b C ceiling, yielding 53 points. Short-term tolerability was reassuring, while long-term and high-risk-population safety remains a separate caution.
Counterpoint. A woman who cannot or does not want to use hormone therapy may experience symptom-scale improvement with the same product under the tested 12-week conditions. Heavy bleeding, a new breast symptom, persistent palpitations or depression, or severe sleep disturbance requires clinical assessment rather than supplement substitution.
Rejudgment record. New verdict — Accepted positive subjective KMI and MENQOL results from one 12-week branded-strain trial but applied the rule ① and ②-b C ceiling for company involvement and no independent replication
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved KMI and MENQOL menopausal symptom scales | C | One 12-week branded YT1 trial was positive, but outcomes were subjective, company researchers participated, and independent replication is absent. |
| Improved objectively measured hot-flash frequency or severity | ? | No independent trial centered on objective counting or physiologic measurement was identified. |
| Long-term efficacy and independent replication | ? | No independent efficacy trial of the same strain beyond 12 weeks was identified. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Lim EY et al. 2020 | Twelve-week multicenter randomized double-blind placebo-controlled trial | 35 | Government-supported Korea Food Research Institute program; Huons-affiliated coauthors and branded-product study | Primary total KMI; modified-KMI items, MENQOL, hormones, endometrium, and safety | Total KMI and all four MENQOL domains improved versus placebo, without clear between-group hormonal or endometrial-thickness changes. | Key positive human evidence; single product and subjective outcomes |
| NCCIH Probiotics safety summary | Official evidence summary | 1 | United States National Center for Complementary and Integrative Health | General probiotic adverse effects and infection in high-risk populations | Summarizes generally reassuring use in healthy people but greater risk in severe illness or immunocompromise. | Safety context, separate from efficacy grade |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] Lactobacillus acidophilus YT1 x improved menopausal symptoms and quality of life — Evidence Grade C·53. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/menolacto-lactobacillus-acidophilus-yt1-menopause-symptoms/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.